262 results on '"McBride, Jacqueline"'
Search Results
2. Local Pentraxin-2 Deficit Is a Feature of Intestinal Fibrosis in Crohn’s Disease
3. Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease.
4. A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling
5. Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19
6. Improving screening and management of latent tuberculosis infection: development and evaluation of latent tuberculosis infection primary care model
7. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
8. Comprehensive profiling of the human fecal proteome from IBD patients with DIA‐MS enables evaluation of disease‐relevant proteins
9. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
10. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*
11. Perinatal mental health screening for women of refugee background: Addressing a major gap in pregnancy care.
12. Perinatal mental health screening for women of refugee background: Addressing a major gap in pregnancy care
13. A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling
14. First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers
15. Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis
16. Profiling of the antibody response to viral and bacterial antigens and its correlations with time-to-hospital discharge: Covacta and Mariposa study
17. Supplementary Figure 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
18. Data from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
19. Supplementary Figure Legends from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
20. Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
21. Supplementary Figure 3 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
22. Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
23. Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
24. Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
25. Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID ‐19
26. A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling.
27. Generation and Protective Ability of Influenza Virus–Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge
28. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
29. Autologous organoid co-culture model reveals T cell-driven epithelial cell death in Crohn’s Disease
30. Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19
31. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial
32. Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
33. Additional file 1 of Improving screening and management of latent tuberculosis infection: development and evaluation of latent tuberculosis infection primary care model
34. 399 MOLECULAR CHARACTERIZATION OF RESPONSE TO ETROLIZUMAB AND ANTI-TNF REVEALS TREATMENT REFRACTORY ULCERATIVE COLITIS IS ASSOCIATED WITH ABUNDANCE OF RESIDUAL NEUTROPHIL SUBSETS AND ACTIVE FIBROBLAST POPULATIONS
35. Mo1781 NON-INVASIVE BIOMARKER AND PATIENT-REPORTED OUTCOMES MODEL TO PREDICT ENDOSCOPIC DISEASE IN ULCERATIVE COLITIS
36. Su1747 REWIRING OF PATHWAY INTERACTIONS IN INFLAMED TISSUE OF ULCERATIVE COLITIS PATIENTS POINTS TO SPECIFIC LIGANDRECEPTOR ACTIVITIES ON NEUTROPHIL AND MACROPHAGE SUBSETS
37. Sa1894 SINGLE-CELL TRAJECTORY ANALYSIS IN MYELOID CELLS REVEALS CELLULAR SUBSTATE SPECIFIC INFORMATION ABOUT THE PATHOBIOLOGY OF ULCERATIVE COLITIS
38. 1137 ELEVATED OSM/OSMR EXPRESSION IN INFLAMED MUCOSAL TISSUE REFLECTS AN INFLAMMATORY CASCADE MEDIATED BY NEUTROPHIL:STROMAL INTERACTIONS ASSOCIATED WITH RESIDUAL DISEASE IN TREATMENT-REFRACTORY UC PATIENTS
39. Tu1745 THE ASSOCIATION OF INTRAEPITHELIAL IMMUNE COMPARTMENT WITH RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
40. Tu1746 SINGLE-CELL TRANSCRIPTOMICS REVEAL TISSUE NEUTROPHIL HETEROGENEITY AND NEUTROPHIL-INFLAMMATORY FIBROBLAST SIGNALING PATHWAYS ASSOCIATED WITH RESISTANCE TO APPROVED THERAPIES IN ULCERATIVE COLITIS
41. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
42. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
43. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
44. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
45. Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease
46. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial
47. Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
48. Genetic deletion of JAM-C reveals a role in myeloid progenitor generation
49. Perinatal psychosocial assessment of women of refugee background
50. Sa447 RESOLUTION IN GENE SIGNATURES ASSOCIATED WITH INFLAMMATORY IMMUNE CELL INFILTRATES, ACTIVATED FIBROBLASTS AND EPITHELIAL RECOVERY IN TNF-NAIVE AND TNF-IR UC PATIENTS TREATED WITH ETROLIZUMAB
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.